MedElevator Войти в исследования
← Поиск публикаций

DOI 10.14336/ad.2025.1308

Медицинская библиотека · Aging and disease · 2026

Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging.

Miao Yan, Wang Wenting, Liu Ye, Zhu Shumai, Li Ye, Zheng Xuehong, Zhuo Dongye, Hua Jiaxin, Zhu Lihan, Zhang Jing, Gu Wenli, Zhang Lin, Zhang Jun, Gu Xiang, Ye Yuanzheng, Wang Fang, Yu Peng, Liu Xiao

СтатьяОбзорПеревод в очереди

Аннотация

Cardiovascular aging, characterized by endothelial dysfunction, arterial stiffening, and myocardial remodeling, is a major contributor to the development of age-related cardiovascular disease. Metformin, a first-line therapy for type 2 diabetes, has attracted interest as a promising geroprotective agent due to its ability to target several fundamental aging pathways. Mechanism: Beyond glucose-lowering effects, metformin may confer cardiovascular benefits through activation of AMP-activated protein kinase and inhibition of mitochondrial complex I. Preclinical work suggests these pathways enhance mitochondrial biogenesis, reduce oxidative stress, promote autophagy, and suppress chronic inflammation. Furthermore, metformin has been reported to modulate epigenetic clocks and support genomic stability, potentially mitigating several hallmarks of aging. Clinical Evidence: Although preclinical evidence is substantial, clinical findings remain heterogeneous. Observational studies and trials like UKPDS suggest cardiovascular benefits, whereas randomized controlled trials (RCTs) such as TAYSIDE, GIPS-III, REMOVAL and GOMET yielded inconsistent results for both clinical and surrogate cardiovascular endpoints. Result interpretations are often limited by relatively small sample sizes and short follow-up durations. Sex Differences and Limitations: Emerging evidence suggests sexual dimorphism in metformin responses, potentially influenced by hormonal status and pharmacokinetics. Additional challenges include the hormetic dose-response, the heterogeneity and frailty of older populations, and the absence of validated aging-specific cardiovascular endpoints. Metformin remains a promising candidate to mitigate cardiovascular aging. However, definitive conclusions regarding its efficacy in non-diabetic older adults will require large-scale, long-term RCTs incorporating aging-related biomarkers and stratification according to sex and metabolic status.

Для цитирования: Miao Yan, Wang Wenting, Liu Ye, Zhu Shumai, Li Ye, Zheng Xuehong, Zhuo Dongye, Hua Jiaxin, Zhu Lihan, Zhang Jing, Gu Wenli, Zhang Lin, Zhang Jun, Gu Xiang, Ye Yuanzheng, Wang Fang, Yu Peng, Liu Xiao. Metformin: A Promising Candidate for Slowing the Progression of Cardiovascular Aging.. Aging and disease. 2026. DOI: 10.14336/ad.2025.1308.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.